Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of Idalopirdine in Healthy Men
NCT02415907Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Apr 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Idalopirdine in Alzheimer's disease (AD), sponsored by Lundbeck. Primary endpoints: Cumulative amounts of radioactivity excreted in urine and faeces and Pharmacokinetic (PK) of idalopirdine and radioactivity in plasma. Started Apr 2015; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02415907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415907.